NCT00681044 · OUTCOME

Hematologic Response Rate

HD Melphalan and SCT in Patients With IGDD or LCDD · Source last updated 2017-04-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: one year

Analysis population: No data were collected or analyzed due to study termination

Groups in this outcome

SCT With Melphalan Conditioning

Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC melphalan: 70-100 mg/m2/day will be administered intravenously on Days -3 and -2 Stem Cell Infusion: infusion of previously collected stem cells on Day 0

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
SCT With Melphalan Conditioning	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

groups

description
Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC melphalan: 70-100 mg/m2/day will be administered intravenously on Days -3 and -2 Stem Cell Infusion: infusion of previously collected stem cells on Day 0
id
OG000
title
SCT With Melphalan Conditioning

population Description

No data were collected or analyzed due to study termination

reporting Status

POSTED

time Frame

one year

title

Hematologic Response Rate

type

PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice